LEO Reports 16-week Results of Tralokinumab in P-III ECZTRA 6 Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis Published: 22 Oct, 2021 | Tags: LEO, Tralokinumab, P-III, ECZTRA 6 Trial, […]readmore
Tags : Beam
Shots: Beam to receive $50M up front & is eligible to receive a target option exercise fees, milestones upon achievement of development & sales milestones along with royalties on sales […]readmore